Clinical Trial

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF).
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2021-02-26; most recent amendment 2026-04-26.
Status change: Not Yet Recruiting → Recruiting 2022-03-18
Trial Details
NCT Number NCT04775706
Lead Sponsor Hanmi Pharmaceutical Company Limited
Conditions Short Bowel Syndrome
Enrollment 18 participants
Start Date 2022-03-03
Primary Completion 2027-12 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12